Показать сообщение отдельно
  #51  
Старый 25.11.2006, 01:12
vladmokh vladmokh вне форума Пол мужской
Начинающий участник
 
Регистрация: 24.01.2006
Город: Санкт - Петербург
Сообщений: 30
Сказал(а) спасибо: 1
vladmokh этот участник имеет хорошую репутацию на форуме
Post

Вот новая статья - и опять не все просто и однозначно:
Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke Lars Ehlers PhD, MSc (econ)*; Grethe Andersen DMSc, PhD, MD; Lone Beltoft Clausen MSc; Merete Bech MSc; and Mette Kjølby PhD, DDS
Background and Purpose--The aim of this study was to assess the costs and cost-effectiveness of intravenous thrombolysis treatment with alteplase (Actilyse) of acute ischemic stroke with 24-hour in-house neurology coverage and use of magnetic resonance imaging.
Methods--A health economic model was designed to calculate the marginal cost-effectiveness ratios for time spans of 1, 2, 3 and 30 years. Effect data were extracted from a meta-analysis of six large-scale randomized and placebo-controlled studies of thrombolytic therapy with alteplase. Cost data were extracted from thrombolysis treatment at Aarhus Hospital, Denmark, and from previously published literature.
Results--The calculated cost-effectiveness ratio after the first year was $55 591 US per quality-adjusted life-year (base case). After the second year, computation of the cost-effectiveness ratio showed that thrombolysis was cost-effective. The long-term computations (30 years) showed that thrombolysis was a dominant strategy compared with conservative treatment given the model premises.
Conclusions--A high-quality thrombolysis treatment with 24-hour in-house neurology coverage and magnetic resonance imaging might not be cost-effective in the short term compared with conservative treatment. In the long term, there are potentially large-scale health economic cost savings.
Ответить с цитированием